CardioPulmonary Vascular Biology COBRE

心肺血管生物学 COBRE

• 批准号: 10630735
• 负责人: Gaurav Choudhary
• 金额: $ 91.35万
• 依托单位: OCEAN STATE RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630735
• 关键词: 2019-nCoV; Advisory Committees; Affect; Area; Award; Biology; Blood Vessels; COVID-19 pandemic; Cardiopulmonary; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Cell Separation; Centers of Research Excellence; Collaborations; Communities; Coronary Arteriosclerosis; Data; Development; Discipline; Disease; Educational workshop; Feedback; Fostering; Funding; Goals; Growth; Home; Human; Infection; Infrastructure; Institution; Investigation; Learning; Legal patent; Lung; Lung diseases; Manuscripts; Mission; Mitochondria; Morbidity - disease rate; Organ; Pathogenesis; Phase; Pilot Projects; Prevention; Productivity; Prognosis; Publishing; Research; Research Personnel; Research Project Grants; Resources; Respiratory Disease; Rhode Island; Scientist; Services; Structure; Vascular Diseases; Virus; Vision; career; catalyst; combat; comorbidity; effective therapy; in vivo imaging; mortality; prevent; programs; pulmonary vascular disorder; respiratory

The vision of the CardioPulmonary Vascular Biology (CPVB) COBRE program is to develop effective approaches to prevent and treat vascular diseases affecting the pulmonary and cardiovascular systems through better understanding of disease mechanisms. This will be accomplished by serving as an interdisciplinary center which promotes collaborative research and provides excellent technical support and resources to investigators. The overall mission of the CPVB COBRE program has been to build the human and technical infrastructure and services that serve as catalysts to increase CPVB research in the state. Cardiovascular and pulmonary diseases are among the leading causes of morbidity and mortality in the US and in the world. Coronary artery disease (CAD) is the leading cause of morbidity and mortality. Respiratory diseases are the 3rd and 4th leading causes of death and are frequently complicated by pulmonary vasculopathy and cardiovascular co-morbidities that markedly worsen prognosis. We have learned that infection with SARS-CoV-2 virus damages multiple organs, with cardiovascular, respiratory, and vascular complications. Thus, there is an important need to understand the pathogenesis of cardiopulmonary vascular diseases in order to develop more effective treatments and prevention. The overall goal of the CPVB COBRE program is to facilitate high impact vascular biology research. The CPVB COBRE program provides infrastructure with administrative, pilot project, and two technical cores, thus providing opportunities to expand areas of investigation, experimental and technical approaches, and scientific collaborations. The specific aims of Phase III CPVB COBRE are to: i) award high-impact research projects in the area of cardiopulmonary vascular biology; ii) provide effective and high-quality services in cell isolation and ex vivo organ function (CIOF), mitochondrial function, and in vivo imaging (MF-II); iii) collaborate with IDeA programs in Rhode Island (RI) and other states to foster scientific networks by providing programming, funding, technical services, and resources to enhance research productivity; and iv) maintain a robust line of investigation in vascular biology that meets the needs of the scientific community and furthers research in prevention and treatment of cardiopulmonary vascular diseases. Continuation of the CPVB COBRE into Phase III will sustain the administrative structure for seminars and workshop planning, engagement, and professional development support of investigators, and expertise in cell isolation and ex vivo organ function, mitochondrial function, and in vivo imaging. We will expand and enrich the vascular biology research community by promoting new collaborations and engaging scientists new to the field from a variety of disciplines. At the end of Phase III, we expect to transition to a sustainable CPVB Center serving as a home to the CVPB research community with high quality core services, significant institutional support, and commitment to continue the development of effective approaches to combat or resolve cardiopulmonary vascular diseases.

肺血管生物学（CPVB）COBRE计划的愿景是开发有效的方法 预防和治疗影响肺和心血管系统的血管疾病， 了解疾病机制。这将通过作为一个跨学科中心来实现， 促进合作研究，并为研究人员提供出色的技术支持和资源。的 中国人民解放军海军陆战队的“眼镜蛇”计划的总的使命是建立人员和技术基础设施， 服务，作为催化剂，以增加CPVB的研究在国家。心血管和肺部疾病 是美国和世界上发病和死亡的主要原因之一。冠状动脉疾病 (CAD)是发病和死亡的主要原因。呼吸系统疾病是第三和第四大原因 死亡率，并经常并发肺血管病变和心血管合并症， 预后明显恶化。我们已经了解到SARS-CoV-2病毒感染会损害多个器官， 心血管呼吸系统和血管并发症因此，有必要了解 心肺血管疾病的发病机制，以开发更有效的治疗方法， 预防CPVB COBRE计划的总体目标是促进高影响力的血管生物学研究。 CPVB COBRE计划提供基础设施，包括管理、试点项目和两个技术核心， 从而为扩大研究领域、实验和技术方法提供机会， 科学合作。第三阶段CPVB COBRE的具体目标是：i）奖励高影响力的研究 心肺血管生物学领域的项目; ii）提供有效和高质量的细胞 分离和离体器官功能（CIOF）、线粒体功能和体内成像（MF-II）; iii）合作 与罗得岛（RI）和其他州的IDEA项目合作，通过提供编程来促进科学网络， 提供资金、技术服务和资源，以提高研究生产力;以及iv）维持一个健全的 满足科学界需要的血管生物学研究，并进一步研究 预防和治疗心肺血管疾病。CPVB COBRE继续进入阶段 III将维持研讨会和讲习班规划、参与和专业人员的行政结构， 研究人员的发展支持，以及细胞分离和离体器官功能，线粒体 功能和体内成像。我们将扩大和丰富血管生物学研究社区，促进 新的合作和从事科学家新的领域从各种学科。在第三阶段结束时， 我们希望过渡到一个可持续的CPVB中心，作为CVPB研究社区的家园， 高质量的核心服务，重要的机构支持，并承诺继续发展 有效的方法来对抗或解决心肺血管疾病。